Also known as · Somatuline Depot
Lanreotide
Long-acting somatostatin analog for acromegaly and NETs.
What it is
Lanreotide (Somatuline Depot) is a long-acting somatostatin analog FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Administered as deep subcutaneous injection.
Mechanism of action
Same somatostatin receptor agonism as octreotide. The depot formulation provides extended duration suitable for monthly dosing.
Approved indications
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors
- Carcinoid syndrome
Why this is out of scope at The Tide
Specialty endocrinology and oncology medication. Acromegaly and neuroendocrine tumors require coordinated specialty care.
Where to learn more
Endocrinology or oncology depending on indication.
Related peptides
From the same category.
Corticotropin
H.P. Acthar Gel · ACTH
Adrenocorticotropic hormone for infantile spasms and MS relapse.